Medical devices containing rapamycin analogs

• US 20030129215A1
• Filed: 09/06/2002
• Published: 07/10/2003
• Est. Priority Date: 09/24/1998
• Status: Abandoned Application

• Current Assignee: Abbott Laboratories
• Original Assignee: T-Ram, Inc.
• Inventors: Burke, Sandra E., Chen, Yen-Chih J., Toner, John L., Cromack, Keith R., Mollison, Karl W., LeCaptain, Angela M., Tarcha, Peter J.
• Application Number:
  US10/235,572
• Publication Number:
  US 20030129215A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61L 2300/254 Enzymes, proenzymes
• CPC Class Codes: A61L 2300/40 characterised by a specific therapeutic activity or mode of action
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/43 Hormones, e.g. dexamethasone
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 498/18 : Bridged systems

Abstract

A medical device comprising a supporting structure having a coating on the surface thereof, the coating containing a therapeutic substance, such as, for example, a drug. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to,

This drug can be used in combination with a drug selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, cytostatic drugs, or combinations of these drugs.

Claims

1. A medical device comprising a supporting structure having a coating on the surface thereof, said coating containing the therapeutic substance

2. The medical device of claim 1, wherein said anti-proliferative agent is an anti-mitotic agent.

3. The medical device of claim 2, wherein said anti-mitotic agent is selected from the group consisting of vinca alkaloids, anti-mitotic alkylating agents, and anti-mitotic metabolites.

4. The medical device of claim 1, wherein said anti-platelet agent is selected from the group consisting of agents that inhibit adhesion of platelets, agents that inhibit aggregation of platelets, and agents that inhibit activation of platelets.

5. The medical device of claim 1, wherein said anti-inflammatory agent is estradiol.

6. The medical device of claim 11, wherein said anti-inflammatory agent is dexamethasone

7. The medical device of claim 1, wherein said supporting structure is selected from the group consisting of coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature.

8. The medical device of claim 1, wherein said coating is polymeric.

9. The medical device of claim 6, wherein said polymeric coating is biostable.

10. The medical device of claim 6, wherein said polymeric coating is biodegradable.

11. The medical device of claim 1, wherein said therapeutic substance is

12. The medical device of claim 1, wherein said therapeutic substance is

13. A medical device comprising a supporting structure having a coating on the surface thereof, said coating containing the therapeutic substance

14. The medical device of claim 13, wherein said anti-proliferative agent an anti-mitotic agent.

15. The medical device of claim 14, wherein said anti-mitotic agent is selected from the group consisting of vinca alkaloids, anti-mitotic alkylating agents, and anti-mitotic metabolites.

16. The medical device of claim 13, wherein said anti-platelet agent is selected from the group consisting of agents that inhibit adhesion of platelets, agents that inhibit aggregation of platelets, and agents that inhibit activation of platelets.

17. The medical device of claim 13, wherein said anti-inflammatory agent is estradiol.

18. The medical device of claim 13, wherein said anti-inflammatory agent is dexamethasone

19. The medical device of claim 13, wherein said supporting structure is selected from the group consisting of coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature.

20. The medical device of claim 13, wherein said coating is polymeric.

21. The medical device of claim 20, wherein said polymeric coating is biostable.

22. The medical device of claim 20, wherein said polymeric coating is biodegradable.

23. A medical device comprising a supporting structure having a coating on the surface thereof, said coating containing the therapeutic substance

24. The medical device of claim 23, wherein said anti-proliferative agent an anti-mitotic agent.

25. The medical device of claim 24, wherein said anti-mitotic agent is selected from the group consisting of vinca alkaloids, anti-mitotic alkylating agents, and anti-mitotic metabolites.

26. The medical device of claim 23, wherein said anti-platelet agent is selected from the group consisting of agents that inhibit adhesion of platelets, agents that inhibit aggregation of platelets, and agents that inhibit activation of platelets.

27. The medical device of claim 23, wherein said anti-inflammatory agent is estradiol.

28. The medical device of claim 23, wherein said anti-inflammatory agent is dexamethasone

29. The medical device of claim 23, wherein said supporting structure is selected from the group consisting of coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature.

30. The medical device of claim 23, wherein said coating is polymeric.

31. The medical device of claim 30, wherein said polymeric coating is biostable.

32. The medical device of claim 30, wherein said polymeric coating is biodegradable.